Orphazyme fails trial in muscle wasting disease
Orphazyme's drug arimoclomol has not shown the desired effect in a pivotal phase II/III trial involving 150 patients with inclusion body myositis (IBM).
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
On Monday morning, Orphazyme was forced to announce that the firm had not seen the results from the phase II/III trial with arimoclomol as treatment for inclusion body myositis (IBM) for which the company management had hoped.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme CFO: 2021 will be the decisive year
For subscribers
